Answer
In rheumatoid arthritis clinical trials, infusion-related reactions occurred during or within 24 hours of the first MabThera (rituximab) infusion in 23% of patients (733/3,189), with incidence decreasing on subsequent infusions.
Sources for this answer
- MabThera 100mg and 500mg Concentrate for Solution for InfusionRoche Products Limited · emc · SmPC §4.8 Undesirable effects · Version 57Document updated
Sources checked